ArticleJournal of cheminformatics2023
How to approach machine learning-based prediction of drug/compound-target interactions.
Article in Journal of cheminformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Machine Learning for RNA-Targeting Drug Design.Journal of chemical information and modeling · 2026Review
- 3DICE: interpretable 3D cross-modal learning for drug-target interaction prediction and large-scale drug discovery.Bioinformatics (Oxford, England) · 2026Article
- FlowDock: A unified flow-based framework for flexible protein-ligand docking and binding affinity prediction.Acta pharmaceutica Sinica. B · 2026Article
- Revolutionizing drug discovery from natural products: The roles of artificial intelligence and multi-omics in accelerating innovation.Acta pharmaceutica Sinica. B · 2026Article
- AI and network biology for rational polypharmacology in signaling drug design: a review.NPJ precision oncology · 2026Review
- AI-driven drug-target interaction prediction: current progress, challenges, and future roadmap for precision medicine.Journal of computer-aided molecular design · 2026Review
- AI and Big Data in Oncology: A Physician-Centered Perspective on Emerging Clinical and Research Applications.Cancer innovation · 2026Review
- Predicting Antileishmanial Activity of Plant-Derived Compounds Using Random Forest Modeling.microPublication biology · 2026Article
- From microfluidics to nanodelivery: artificial intelligence reshapes neuropharmacology research strategies.Frontiers in pharmacology · 2026Review
- Large Language Models in Critical Care Medicine: Scoping Review.JMIR medical informatics · 2025Article
- Predicting drug-target affinity through triple pre-activated random residual planet convolution coupled attention network and contact maps.Journal of computer-aided molecular design · 2025Article
- QKDTI A quantum kernel based machine learning model for drug target interaction prediction.Scientific reports · 2025Article
- The diagnostic and prognostic value ofBioImpacts : BI · 2025Article
- DTGHAT: multi-molecule heterogeneous graph transformer based on multi-molecule graph for drug-target identification.Frontiers in pharmacology · 2025Article
- The G Protein-Coupled Receptor-Related Gene Signatures for Diagnosis and Prognosis in Glioblastoma: A Deep Learning Model Using RNA-Seq Data.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- QSPRpred: a Flexible Open-Source Quantitative Structure-Property Relationship Modelling Tool.Journal of cheminformatics · 2024Article
- Causal enhanced drug-target interaction prediction based on graph generation and multi-source information fusion.Bioinformatics (Oxford, England) · 2024Article
- Article
- Artificial intelligence and bioinformatics: a journey from traditional techniques to smart approaches.Gastroenterology and hepatology from bed to bench · 2024Review
- The recent advances in the approach of artificial intelligence (AI) towards drug discovery.Frontiers in chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The identification of drug/compound-target interactions (DTIs) constitutes the basis of drug discovery, for which computational predictive approaches have been developed. As a relatively new data-driven paradigm, proteochemometric (PCM) modeling utilizes both protein and compound properties as a pair at the input level and processes them via statistical/machine learning. The representation of input samples (i.e., proteins and their ligands) in the form of quantitative feature vectors is crucial for the extraction of interaction-related properties during the artificial learning and subsequent prediction of DTIs. Lately, the representation learning approach, in which input samples are automatically featurized via training and applying a machine/deep learning model, has been utilized in biomedical sciences. In this study, we performed a comprehensive investigation of different computational approaches/techniques for protein featurization (including both conventional approaches and the novel learned embeddings), data preparation and exploration, machine learning-based modeling, and performance evaluation with the aim of achieving better data representations and more successful learning in DTI prediction. For this, we first constructed realistic and challenging benchmark datasets on small, medium, and large scales to be used as reliable gold standards for specific DTI modeling tasks. We developed and applied a network analysis-based splitting strategy to divide datasets into structurally different training and test folds. Using these datasets together with various featurization methods, we trained and tested DTI prediction models and evaluated their performance from different angles. Our main findings can be summarized under 3 items: (i) random splitting of datasets into train and test folds leads to near-complete data memorization and produce highly over-optimistic results, as a result, should be avoided, (ii) learned protein sequence embeddings work well in DTI prediction and offer high potential, despite interaction-related properties (e.g., structures) of proteins are unused during their self-supervised model training, and (iii) during the learning process, PCM models tend to rely heavily on compound features while partially ignoring protein features, primarily due to the inherent bias in DTI data, indicating the requirement for new and unbiased datasets. We hope this study will aid researchers in designing robust and high-performing data-driven DTI prediction systems that have real-world translational value in drug discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.